There were a total of 6 deaths, including 3 cases in the roxadustat group (1 case of peritonitis, 1 case of cerebral infarction, and 1 case of arrhythmia) and the other 3 cases in the EPO group (1 case of peritonitis, 1 case of gastrointestinal hemorrhage, and 1 case of heart failure). Here, EPO is linked to cerebral infarction.